Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high‐risk relapsed/refractory chronic lymphocytic leukemia patients

Optimal treatment strategies are lacking in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Gemcitabine has shown activity and acceptable safety profile in B‐cell lymphomas. We present a retrospective case review of gemcitabine and alemtuzumab, every 21 d (for up to six courses) in 27 community‐based patients with high‐risk R/R CLL. Median age was 70 yr (44–83 yr), 55% patients had Binet stage C, deletion 17p (del(17p)) and/or deletion 11q (del(11q)) were found in 65% and 27%, bulky disease in 55.5%, and fludarabine‐refractoriness in 48% of cases, respectively. Overall response rate was 63% (29.6% clinical CR and 33.4% PR). At a median follow‐up of 31 months, median PFS and OS were 15.4 and 24 months. In multivariate analysis, median OS is influenced by prior lines of treatment = 3 and bulky disease. Combination of alemtuzumab and gemcitabine appears to be an active, easy to administrate treatment in routine practice, high‐risk R/R CLL patients.

[1]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[2]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[3]  F. Rodeghiero,et al.  The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic leukemia , 2013, American journal of hematology.

[4]  J. Neffendorf,et al.  Ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[5]  A. Pettitt,et al.  Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Gribben,et al.  Risk categories and refractory CLL in the era of chemoimmunotherapy. , 2012, Blood.

[7]  M. Hallek,et al.  Alemtuzumab for patients with chronic lymphocytic leukaemia. , 2012, The Cochrane database of systematic reviews.

[8]  R. Foà,et al.  An Italian retrospective study on the routine clinical use of low‐dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients , 2012, British journal of haematology.

[9]  M. Hallek,et al.  Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. , 2011, The Lancet. Oncology.

[10]  H. Döhner,et al.  Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW , 2011 .

[11]  W. Wierda,et al.  Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. , 2011, Blood.

[12]  V. Petrizzi,et al.  Clinical Trials and Observations , 2022 .

[13]  R. Greil,et al.  Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Michael Hallek,et al.  Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. , 2009, Blood.

[15]  R. Schlenk,et al.  Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Kipps,et al.  Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Kantarjian,et al.  The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy , 2007, Leukemia & lymphoma.

[18]  R. Greil,et al.  Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemia , 2006, Cancer.

[19]  H. Döhner,et al.  Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. , 2002, The New England journal of medicine.

[20]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[21]  G. Salles,et al.  Gemcitabine as a single agent in the treatment of relapsed or refractory low‐grade non‐Hodgkin's lymphoma , 2001, British journal of haematology.

[22]  M. Grever,et al.  Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia. , 2001, Leukemia research.

[23]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[24]  W. Hiddemann,et al.  Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Allerheiligen,et al.  Preclinical, pharmacologic, and phase I studies of gemcitabine. , 1997, Seminars in oncology.

[26]  D. Carson,et al.  Quantitative immunoassay of human deoxycytidine kinase in malignant cells. , 1992, Analytical biochemistry.